Relmada Therapeutics Inc.
The New York-based pharmaceutical company offered 3,833,334 shares at $30 apiece, including 500,000 shares as part of underwriters' overallotment option.
Relmada intends to use the gross proceeds from the offering to fund the research and development of its treatment-resistant depression drug REL-1017, or dextromethadone, and for general corporate purposes.
Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.